First Time Loading...

Theratechnologies Inc
TSX:TH

Watchlist Manager
Theratechnologies Inc Logo
Theratechnologies Inc
TSX:TH
Watchlist
Price: 2.23 CAD 12.63% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

Theratechnologies, Inc. is a pharmaceutical company. [ Read More ]

The intrinsic value of one TH stock under the Base Case scenario is 9.31 CAD. Compared to the current market price of 2.23 CAD, Theratechnologies Inc is Undervalued by 76%.

Key Points:
TH Intrinsic Value
Base Case
9.31 CAD
Undervaluation 76%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Theratechnologies Inc

Backtest TH Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling TH stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of Theratechnologies Inc's business.

What risks and challenges
does Theratechnologies Inc face in the near future?

Summarize the latest earnings report
of Theratechnologies Inc.

Provide P/E
for Theratechnologies Inc and its competitors.

Financials

Balance Sheet Decomposition
Theratechnologies Inc

Current Assets 40.6m
Cash & Short-Term Investments 22.9m
Receivables 9.1m
Other Current Assets 8.6m
Non-Current Assets 16.1m
PP&E 2.2m
Intangibles 12.9m
Other Non-Current Assets 1.1m
Current Liabilities 97.7m
Accounts Payable 30.5m
Other Current Liabilities 67.2m
Non-Current Liabilities 734k
Long-Term Debt 684k
Other Non-Current Liabilities 50k
Efficiency

Earnings Waterfall
Theratechnologies Inc

Revenue
79.7m USD
Cost of Revenue
-20.5m USD
Gross Profit
59.3m USD
Operating Expenses
-78.3m USD
Operating Income
-19m USD
Other Expenses
-10.1m USD
Net Income
-29.1m USD

Free Cash Flow Analysis
Theratechnologies Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

TH Profitability Score
Profitability Due Diligence

Theratechnologies Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional ROE
ROE is Increasing
Positive 3-Years Revenue Growth
36/100
Profitability
Score

Theratechnologies Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

TH Solvency Score
Solvency Due Diligence

Theratechnologies Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
35/100
Solvency
Score

Theratechnologies Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TH Price Targets Summary
Theratechnologies Inc

Wall Street analysts forecast TH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TH is 6.55 CAD with a low forecast of 4.9 CAD and a high forecast of 8.4 CAD.

Lowest
Price Target
4.9 CAD
120% Upside
Average
Price Target
6.55 CAD
194% Upside
Highest
Price Target
8.4 CAD
277% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

TH Price
Theratechnologies Inc

1M 1M
+11%
6M 6M
-22%
1Y 1Y
-48%
3Y 3Y
-88%
5Y 5Y
-93%
10Y 10Y
+25%
Annual Price Range
2.23
52w Low
1.24
52w High
5.52
Price Metrics
Average Annual Return -28.97%
Standard Deviation of Annual Returns 35.18%
Max Drawdown -96%
Shares Statistics
Market Capitalization 102.5m CAD
Shares Outstanding 45 980 000
Percentage of Shares Shorted 0.03%

TH Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Theratechnologies Inc Logo
Theratechnologies Inc

Country

Canada

Industry

Biotechnology

Market Cap

102.5m CAD

Dividend Yield

0%

Description

Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).

Contact

QUEBEC
MONTREAL
2015 Peel Street, 5Th Floor
+5143367800.0
http://www.theratech.com/

IPO

1993-12-21

Employees

87

Officers

President, CEO & Director
Mr. Paul Lévesque
Senior VP & CFO
Mr. Philippe Dubuc M.B.A., MBA
General Counsel & Corporate Secretary
Mr. Jocelyn Lafond L.L.M., LL.B.
Senior VP & Chief Medical Officer
Dr. Christian Marsolais Ph.D.
Global Commercial Officer
Mr. John Leasure
Vice President of Human Resources
Hon. Andre Dupras M.Sc.

See Also

Discover More
What is the Intrinsic Value of one TH stock?

The intrinsic value of one TH stock under the Base Case scenario is 9.31 CAD.

Is TH stock undervalued or overvalued?

Compared to the current market price of 2.23 CAD, Theratechnologies Inc is Undervalued by 76%.